187 related articles for article (PubMed ID: 32553246)
1. Complement-Based Therapy in the Management of Antibody-Mediated Rejection.
Bhalla A; Alachkar N; Alasfar S
Adv Chronic Kidney Dis; 2020 Mar; 27(2):138-148. PubMed ID: 32553246
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
[TBL] [Abstract][Full Text] [Related]
3. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
Stegall MD; Diwan T; Raghavaiah S; Cornell LD; Burns J; Dean PG; Cosio FG; Gandhi MJ; Kremers W; Gloor JM
Am J Transplant; 2011 Nov; 11(11):2405-13. PubMed ID: 21942930
[TBL] [Abstract][Full Text] [Related]
4. Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.
Montgomery RA; Orandi BJ; Racusen L; Jackson AM; Garonzik-Wang JM; Shah T; Woodle ES; Sommerer C; Fitts D; Rockich K; Zhang P; Uknis ME
Am J Transplant; 2016 Dec; 16(12):3468-3478. PubMed ID: 27184779
[TBL] [Abstract][Full Text] [Related]
5. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
[TBL] [Abstract][Full Text] [Related]
6. Complement Interception Across Humoral Incompatibility in Solid Organ Transplantation: A Clinical Perspective.
Biglarnia AR; Ekdahl KN; Nilsson B
Adv Exp Med Biol; 2015; 865():211-33. PubMed ID: 26306452
[TBL] [Abstract][Full Text] [Related]
7. Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.
Jordan SC; Choi J; Kahwaji J; Vo A
Transplant Proc; 2016 Apr; 48(3):806-8. PubMed ID: 27234741
[TBL] [Abstract][Full Text] [Related]
8. Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation.
Berger M; Lefaucheur C; Jordan SC
Transplantation; 2019 Sep; 103(9):1763-1775. PubMed ID: 30946220
[TBL] [Abstract][Full Text] [Related]
9. Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation.
Schwotzer N; Paganetti G; Barchi M; Perrottet N; Aubert V; Sadallah S; Rotman S; Venetz JP; Matter M; Golshayan D; Pascual M
Xenotransplantation; 2020 Jul; 27(4):e12630. PubMed ID: 32698246
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
[TBL] [Abstract][Full Text] [Related]
11. Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases.
Tan EK; Bentall A; Dean PG; Shaheen MF; Stegall MD; Schinstock CA
Transplantation; 2019 Nov; 103(11):2397-2404. PubMed ID: 30801549
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
13. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.
Lefaucheur C; Viglietti D; Hidalgo LG; Ratner LE; Bagnasco SM; Batal I; Aubert O; Orandi BJ; Oppenheimer F; Bestard O; Rigotti P; Reisaeter AV; Kamar N; Lebranchu Y; Duong Van Huyen JP; Bruneval P; Glotz D; Legendre C; Empana JP; Jouven X; Segev DL; Montgomery RA; Zeevi A; Halloran PF; Loupy A
J Am Soc Nephrol; 2018 Feb; 29(2):620-635. PubMed ID: 29042454
[TBL] [Abstract][Full Text] [Related]
14. Donor-specific HLA antibody-mediated complement activation is a significant indicator of antibody-mediated rejection and poor long-term graft outcome during lung transplantation: a single center cohort study.
Roux A; Thomas KA; Sage E; Suberbielle-Boissel C; Beaumont-Azuar L; Parquin F; Le Guen M; Harre N; Hamid AM; Reed EF
Transpl Int; 2018 Jul; 31(7):761-772. PubMed ID: 29537702
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
[TBL] [Abstract][Full Text] [Related]
16. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH;
Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541
[TBL] [Abstract][Full Text] [Related]
18. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
[TBL] [Abstract][Full Text] [Related]
20. The role of anticomplement therapy in the management of the kidney allograft.
Kanbay M; Copur S; Yilmaz ZY; Baydar DE; Bilge I; Susal C; Kocak B; Ortiz A
Clin Transplant; 2024 Mar; 38(3):e15277. PubMed ID: 38485664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
